83 results
8-K
AXLA
Axcella Health Inc.
12 Nov 19
Results of Operations and Financial Condition
4:04pm
)
Completed enrollment of a non-IND clinical study to assess the impact of AXA1125/AXA1957 on safety, tolerability and physiological impact in more than … 100 adult subjects with NAFLD
Initiated enrollment of a non-IND clinical study to assess the impact of AXA1957 on safety, tolerability
UPLOAD
AXLA
Axcella Health Inc.
19 Feb 19
Letter from SEC
12:00am
Program, page 116
6. We note your disclosure on page 117 that the EMM Safety Database
"synthesizes our own
and third-party data on dose … ranges for each EMM or combinations of
EMM previously
studied in humans without any or significant safety issues" and your
disclosure on page
8-K
EX-99.1
AXLA
Axcella Health Inc.
17 Mar 21
Axcella Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
7:44am
, placebo-controlled, multi-center trial evaluating the efficacy and safety of AXA1665 in patients who have experienced at least one prior OHE event and have … and randomized 1:1 to receive either 53.8 grams per day of AXA1665 or a calorie-matched placebo in three divided doses for 24 weeks, with a four-week safety
8-K
EX-99.1
AXLA
Axcella Health Inc.
10 Nov 21
Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials
8:08am
-controlled investigation to evaluate the efficacy and safety of AXA1125 in approximately 40 patients with exertional fatigue related to Long COVID … ). EMMPOWER is a global 24-week, randomized, double-blind, placebo-controlled trial that is evaluating the efficacy and safety of AXA1665
8-K
EX-99.1
AXLA
Axcella Health Inc.
11 May 20
Axcella Reports First Quarter Financial Results and Provides Business Update
8:13am
AXA1125-003, a clinical study assessing the impact of AXA1125 and AXA1957 on safety, tolerability and physiology in subjects with non-alcoholic fatty liver … clinical study assessing the impact of AXA1665 on safety, tolerability and physiology in adult subjects with mild and moderate hepatic insufficiency
8-K
EX-99.1
2tv7jd2po 0013sbp
5 Aug 20
Axcella Reports Positive Top-Line Data from AXA1665-002 and Second Quarter Financial Results
8:22am
8-K
EX-99.2
109345id
29 Sep 22
Regulation FD Disclosure
9:15am
8-K
EX-99.2
8no2 mg2hgy
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
8-K
EX-99.1
0n86ayzy
23 Mar 20
Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
4:03pm
S-1
7kt1xc0 kbkq8
12 Apr 19
IPO registration
7:02am
8-K
EX-99.1
oyfxwqjsl7yai
30 Mar 22
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
8:05am
10-K
2pipz8hois1aeduzlbh
23 Mar 20
Annual report
4:12pm
8-K
EX-99.1
wgahvgwd6snvr7j0f
29 Jul 21
Axcella Reports Second Quarter Financial Results and Provides Business Update
7:58am
DRSLTR
34mh7durzvhpf3o4lzb9
15 Mar 19
Correspondence regarding draft registration statement
12:00am
424B4
s6c a7romn4e0
9 May 19
Prospectus supplement with pricing info
4:29pm
S-1/A
m1t7to5f8yt3mb88
30 Apr 19
IPO registration (amended)
6:06am
DRS/A
xislp
15 Mar 19
Draft registration statement (amended)
12:00am